Close Menu

By Doug Macron

With its ability to down-regulate almost any gene of interest, RNAi has been touted as a technology with almost limitless therapeutic potential, capable of hitting targets that have eluded traditional modalities such as small molecules.

Despite this promise, companies working in the space have taken a decidedly measured approach in building their internal pipelines, focusing on a relatively small number of drug-development programs.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

The Wall Street Journal reports on the struggle to meet the demand for rapid COVID-19 testing.

The Newsroom reports New Zealand is using genomics to trace the origins of its new coronavirus outbreak.

In Nature this week: researchers in Canada sequence the genome of the black mustard plant Brassica nigra, and more.

According to Bloomberg, Moderna has a $1.5 billion vaccine deal with the US to provide 100 million doses.